Compare Stocks: AIM, NICXF, AKTX, and ATYR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$0.17 +5.3%	$0.22	$0.16 ▼ $2.88	$5.18M	1.27	11.67 million shs	1.02 million shs
AKTX Akari Therapeutics	$8.84 +21.4%	$9.12	$3.02 ▼ $33.60	$20.24M	1.43	277,131 shs	55,689 shs
ATYR aTyr Pharma	$0.18 +0.3%	$0.42	$0.18 ▼ $1.11	$18.03M	0.91	2.50 million shs	2.22 million shs
NICXF Nicox	$0.30	$0.30	$0.25 ▼ $0.30	$20.68M	0.03	N/A	N/A

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	-4.77%	-11.49%	-27.41%	-40.73%	-93.89%
AKTX Akari Therapeutics	-7.85%	-15.64%	-34.06%	-36.70%	-81.43%
ATYR aTyr Pharma	-8.85%	-34.14%	-52.83%	-64.47%	-82.38%
NICXF Nicox	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$0.17 +5.3%	$0.22	$0.16 ▼ $2.88	$5.18M	1.27	11.67 million shs	1.02 million shs
AKTX Akari Therapeutics	$8.84 +21.4%	$9.12	$3.02 ▼ $33.60	$20.24M	1.43	277,131 shs	55,689 shs
ATYR aTyr Pharma	$0.18 +0.3%	$0.42	$0.18 ▼ $1.11	$18.03M	0.91	2.50 million shs	2.22 million shs
NICXF Nicox	$0.30	$0.30	$0.25 ▼ $0.30	$20.68M	0.03	N/A	N/A

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	-4.77%	-11.49%	-27.41%	-40.73%	-93.89%
AKTX Akari Therapeutics	-7.85%	-15.64%	-34.06%	-36.70%	-81.43%
ATYR aTyr Pharma	-8.85%	-34.14%	-52.83%	-64.47%	-82.38%
NICXF Nicox	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	2.50	Moderate Buy	$9.00	5,184.79% Upside
AKTX Akari Therapeutics	2.80	Moderate Buy	$32.33	265.76% Upside
ATYR aTyr Pharma	2.67	Moderate Buy	N/A	N/A
NICXF Nicox	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AIM, NICXF, AKTX, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/18/2026	AKTX Akari Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/16/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Buy	$30.00
7/15/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$90K	57.60	N/A	N/A	($2.99) per share	-0.06
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
ATYR aTyr Pharma	$190K	94.89	N/A	N/A	$0.69 per share	0.27
NICXF Nicox	$3.59M	5.76	N/A	N/A	$0.05 per share	6.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$13.96M	-$24.68	N/A	N/A	N/A	-15,021.05%	N/A	-143.02%	N/A
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	12/4/2026 (Estimated)
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
NICXF Nicox	-$24.23M	N/A	N/A	15.00	N/A	N/A	N/A	N/A	N/A

Latest AIM, NICXF, AKTX, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ATYR aTyr Pharma	-$0.11	N/A	N/A	N/A	$2.50 million	N/A
8/7/2026	Q2 2026	AIM AIM ImmunoTech	N/A	-$0.43	N/A	-$0.43	N/A	$0.03 million
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
NICXF Nicox	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	N/A	2.11	2.11
AKTX Akari Therapeutics	N/A	0.60	0.60
ATYR aTyr Pharma	N/A	5.12	5.12
NICXF Nicox	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
AKTX Akari Therapeutics	5.06%
ATYR aTyr Pharma	61.72%
NICXF Nicox	N/A

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.82%
AKTX Akari Therapeutics	30.00%
ATYR aTyr Pharma	5.03%
NICXF Nicox	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	21	30.44 million	30.19 million	Not Optionable
AKTX Akari Therapeutics	5	2.29 million	1.60 million	Not Optionable
ATYR aTyr Pharma	58	98.09 million	93.15 million	Optionable
NICXF Nicox	28	68.92 million	N/A	Not Optionable

AIM, NICXF, AKTX, and ATYR Headlines

Recent News About These Companies

NICOX SA: Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026

September 16, 2026 | finanznachrichten.de

Nicox to Present Phase 3 NCX 470 Glaucoma Data at AAOpt 2026

September 16, 2026 | tipranks.com

Nicox Extends Cash Runway as NCX 470 Nears Key Regulatory Milestones

September 2, 2026 | tipranks.com

Nicox Announces Extension of Cash Runway

September 2, 2026 | markets.businessinsider.com

Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma

August 27, 2026 | markets.businessinsider.com

Nicox Gets 2027 FDA Decision Date for Glaucoma Drug NCX 470

August 27, 2026 | tipranks.com

Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment

July 1, 2026 | markets.businessinsider.com

Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company

June 24, 2026 | taiwannews.com.twT

NICOX SA: Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470

June 18, 2026 | finanznachrichten.de

Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470

June 18, 2026 | markets.businessinsider.com

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative

June 4, 2026 | markets.businessinsider.com

NICOX SA: Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026

April 21, 2026 | finanznachrichten.de

Nicox (NICXF) Upgraded to Buy: Here's Why

March 9, 2026 | zacks.com

NICOX SA: Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting

February 25, 2026 | finanznachrichten.de

Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting

February 24, 2026 | markets.businessinsider.com

NICOX SA: Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470

February 16, 2026 | finanznachrichten.de

Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470

February 16, 2026 | finance.yahoo.com

NICOX SA: Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

February 11, 2026 | finanznachrichten.de

Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

February 11, 2026 | finance.yahoo.com

Nicox: Strengthened Balance Sheet and De-Risked NCX 470 Pivotal Data Support Reiterated Buy Rating

January 6, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AIM, NICXF, AKTX, and ATYR Company Descriptions

AIM ImmunoTech NYSEAMERICAN:AIM

$0.17 +0.01 (+5.25%)

Closing price 04:10 PM Eastern

Extended Trading

$0.17 0.00 (-0.18%)

As of 06:47 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Akari Therapeutics NASDAQ:AKTX

$8.84 +1.56 (+21.43%)

Closing price 03:59 PM Eastern

Extended Trading

$8.61 -0.23 (-2.60%)

As of 06:12 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

aTyr Pharma NASDAQ:ATYR

$0.18 +0.00 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$0.19 +0.01 (+2.83%)

As of 06:53 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Nicox OTCMKTS:NICXF

$0.30 0.00 (0.00%)

As of 10/14/2026

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AIM, NICXF, AKTX, and ATYR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AIM, NICXF, AKTX, and ATYR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AIM, NICXF, AKTX, and ATYR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AIM, NICXF, AKTX, and ATYR Company Descriptions

AIM ImmunoTech NYSEAMERICAN:AIM

Akari Therapeutics NASDAQ:AKTX

aTyr Pharma NASDAQ:ATYR

Nicox OTCMKTS:NICXF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AIM, NICXF, AKTX, and ATYR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AIM, NICXF, AKTX, and ATYR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AIM, NICXF, AKTX, and ATYR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AIM, NICXF, AKTX, and ATYR Company Descriptions

AIM ImmunoTech NYSEAMERICAN:AIM

Akari Therapeutics NASDAQ:AKTX

aTyr Pharma NASDAQ:ATYR

Nicox OTCMKTS:NICXF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools